Fox Chase Cancer Center Announces New Immunotherapy Clinical Trial for Breast Cancer Patients

Lori Goldstein, MD
Lori Goldstein, MD

PHILADELPHIA (May 15, 2017) – Patients with some types of breast cancer will have a new clinical trial option at Fox Chase Cancer Center. Medical oncologists Lori Goldstein, MD, and Elias Obeid, MD, MPH, are opening a phase 2 immunotherapy clinical trial for newly diagnosed, locally recurrent, or metastatic HER2-overexpressing breast cancer.

The doctors are seeking to learn how an anti-PD-L1 immunotherapy drug called atezolizumab works when used in combination with the standard of care regimen of paclitaxel, pertuzumab, and trastuzumab. This clinical trial will study both the safety and efficacy of the drug combination in treating this type of breast cancer. Researchers on the team will also study biomarkers to learn more about how effective this combination will be at attacking the cancer on a molecular level.

Elias Obeid, MD, MPH
Elias Obeid, MD, MPH

As a National Cancer Institute-designated Comprehensive Cancer Center, Fox Chase offers patients the most advanced treatment options through clinical trials, many of which are not available elsewhere. The faculty includes many nationally ranked doctors who specialize in the development of these studies — specifically phase 1 and 2 trials.

Goldstein and Obeid are seeking 50 patients over the age of 18 who have locally recurrent, unresectable, or metastatic HER2-overexpressing breast cancer to participate in this study. Eligible patients may have received one prior hormonal treatment for metastatic disease.

This study will be open soon. 

Learn more about clinical trials offered at Fox Chase.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text